Last reviewed · How we verify
Concurrent chemotherapy and KN026
KN026 is a monoclonal antibody targeting PD-L1.
KN026 is a monoclonal antibody targeting PD-L1. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | Concurrent chemotherapy and KN026 |
|---|---|
| Also known as | docetaxol |
| Sponsor | Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
KN026 works by binding to PD-L1, preventing it from interacting with PD-1 and thereby enhancing the body's immune response against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Rash
- Pyrexia
Key clinical trials
- Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: